Tislelizumab—A Promising New Option for Enhancing Chemotherapy Benefit in Treatment for Advanced Squamous Cell Lung Cancer
Mené en Chine sur 355 patients atteints d'un cancer épidermoïde du poumon non à petites cellules de stade avancé (âge médian : 62 ans), cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout du tislélizumab à une chimiothérapie de première ligne (durée médiane de suivi : 8,6 mois)
These are exciting times in thoracic oncology. A worldwide cadre of investigators is collaborating effectively with industry and other funders of clinical trials to quickly bring highly effective drugs to the point of routine care delivery. These drugs are already profoundly affecting population-level lung cancer statistics, at least in the US. In RATIONALE 307, triplet therapy with the new high-affinity programmed cell death protein 1 inhibitor tislelizumab in combination with 2 carboplatin/taxane doublets was tested against a standard carboplatin/paclitaxel doublet in an open-label randomized clinical trial that involved 360 patients with squamous cell lung cancer who were recruited from 46 sites in China. One-third of the cohort had stage IIIB cancer, and two-thirds had stage IV disease by the seventh edition lung cancer staging criteria.
JAMA Oncology , commentaire, 2020